CLGN:NSD-CollPlant Biotechnologies Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 13.71

Change

-0.18 (-1.30)%

Market Cap

USD 0.13B

Volume

0.08M

Average Target Price

USD 26.00 (+89.64%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel. Address: Weizmann Science Park, Rehovot, Israel, 7670104

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-10.59 (-6.73%)

USD62.28B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.68 (+0.80%)

USD54.69B 20.45 15.08
REGN Regeneron Pharmaceuticals, Inc

-8.19 (-1.77%)

USD49.61B 15.17 11.55
ALXN Alexion Pharmaceuticals, Inc

-1.60 (-1.05%)

USD33.27B 55.63 33.22
RPRX Royalty Pharma plc

-1.08 (-2.25%)

USD29.16B 22.60 14.17
BGNE BeiGene, Ltd

-12.93 (-4.05%)

USD29.03B N/A N/A
SGEN Seagen Inc

+1.16 (+0.76%)

USD27.64B 45.27 37.70
BNTX BioNTech SE

-5.23 (-4.75%)

USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.29 (-3.67%)

USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CLGN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.30% 67% D+ 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.30% 67% D+ 75% C
Trailing 12 Months  
Capital Gain 8.64% 36% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.64% 36% F 33% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 29.65% 67% D+ 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.65% 67% D+ 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 53.29% 52% F 25% F
Risk Adjusted Return 55.63% 81% B- 75% C
Market Capitalization 0.13B 20% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 19.46 13% F 9% F
Price / Cash Flow Ratio -22.33 75% C 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -267.78% 10% F 3% F
Return on Invested Capital -171.17% 11% F 5% F
Return on Assets -26.72% 50% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.02 100% A+ 99% A+
Short Percent N/A N/A N/A N/A N/A
Beta 0.66 82% B- 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector